Welcome to our dedicated page for Liveworld news (Ticker: LVWD), a resource for investors and traders seeking the latest updates and insights on Liveworld stock.
LiveWorld reports news on its business as a human-led, AI-powered digital marketing agency and software company serving healthcare, pharmaceutical and other regulated brands. Company updates focus on social and digital media compliance, expert-led moderation, community engagement, AI-powered insights, and software-enabled customer experience programs.
Recurring developments include financial results, investment in AI-based products, healthcare-ready search optimization services spanning GEO, AIO and SEO, and AI Brand Reputation Index research for pharmaceutical and OTC consumer healthcare brands. LiveWorld’s disclosures also describe how its offerings combine human review, regulatory expertise and AI tools for brand engagement and reputation intelligence.
LiveWorld (OTC: LVWD) reported second quarter 2026 revenues of approximately $2.9 million, up about 9% from $2.7 million a year earlier, with healthcare revenues of $2.6 million. For the first six months of 2026, revenues were about $5.8 million, a 12% increase from $5.2 million in 2025.
The company recorded a Q2 2026 net loss of approximately $187,000 (6% of revenues), compared with a $92,000 loss in Q2 2025, which management attributed to higher investment in its LiveInsight AI product. For the first half, net loss narrowed to about $290,000 from $368,000. LiveWorld ended June 30, 2026 with $7.4 million in cash and cash equivalents and net cash available for operations of $6.5 million, compared with $5.7 million at year-end 2025.
Management stated that rollout of LiveInsight AI, its flagship intelligence system, remains on track for Fall 2026, and expects continued increased investment in development and marketing to affect operating income in the second half of 2026.
LiveWorld (OTC: LVWD) appointed Rob Thomas as Vice President, Creative Director, to support growth in its healthcare digital agency business. Thomas brings over 18 years of pharmaceutical creative leadership and AI-driven innovation experience.
He will lead a second creative team serving Fortune 100 healthcare and pharmaceutical clients across omnichannel digital campaigns.
LiveWorld (OTC: LVWD) marked its 30th anniversary by outlining a strategic shift to a Human-Led, AI-Powered intelligence systems company focused on the emerging Intelligence Economy.
The company introduced its flagship LiveInsight AI™ platform, with 12 patents pending, and announced that the CEO and all five non-executive directors intend to buy LVWD stock on the open market in a two-week window starting June 8, 2026.
LiveWorld (OTC: LVWD) launched LiveInsight AI, a Human-Led, AI-Powered intelligence system for pharma marketers that converts complex healthcare conversations and medical data into decision-grade insights in minutes.
Features include disease-state libraries, discovery intelligence engines, brand customization, compliance workflows, and 13 patent-pending mechanisms to reduce AI hallucinations, with rollout beginning this summer.
LiveWorld (OTC:LVWD) launched its Advanced Practice Provider (APP) Program, centered on a new APP Research Council of practicing NPs and PAs across 30+ specialties. The initiative targets an overlooked audience that writes about 27% of prescriptions and influences over half of prescribing decisions.
The program offers direct APP feedback, media strategy optimization, and digital-first creative aligned with APP behavior, aiming to expand reach and improve campaign performance for pharmaceutical brands.
LiveWorld (OTC: LVWD) reported Q1 2026 revenue of $2.95 million, up about 15% year over year, with healthcare revenue of $2.8 million, up about 19%.
Net loss narrowed to $103,000 from $276,000. Cash and equivalents were $6.8 million, with net cash available for operations of $5.5 million.
LiveWorld (OTC: LVWD) reported 2025 results: $11.1M total revenue, down ~2% year-over-year, and $326K net income (3% margin), a ~376% increase versus 2024. Cash and cash equivalents were $7.313M, with net cash available for operations of $5.7M.
Management said LiveWorld increased AI investment, launched new AI solutions, and is cautiously optimistic 2026 revenues will exceed 2025 based on current bookings.
LiveWorld (OTC: LVWD) launched an integrated GEO, AIO & SEO search optimization service on March 3, 2026 to help healthcare and regulated brands manage visibility, accuracy, and authority as search shifts toward AI-generated answers.
The solution combines audits, prompt/keyword intelligence, and AI-optimized content with human review to reduce misrepresentation and compliance risk in AI-driven discovery.
LiveWorld (OTC: LVWD) unveiled a Human-Led, AI-Powered Strategy & 2026 Solutions Roadmap on January 21, 2026, introducing seven AI solutions for healthcare marketing. The roadmap blends decades of human-reviewed conversation data, regulatory expertise, and platform engineering to deliver AI that prioritizes safety, governance, and empathy.
Available now: AI Brand Reputation Reports and a new AI Chatbot Moderation service; three additional AI web-management tools and a human-led intelligence product are slated for Q1 2026, and a learning/discovery solution for Q2 2026. Company cites top-10 pharma clients using its AI today.
LiveWorld (OTC: LVWD) reported Q3 2025 results on November 13, 2025: Total revenue $2.84M (healthcare revenue $2.6M) and net income $195K for the quarter. Q3 revenue declined ~9% versus Q3 2024 and nine-month revenue was $8.07M versus $8.49M a year earlier. The company ended Q3 with $7.69M cash and cash equivalents and defined net cash available for operations of $6.0M. Deferred revenue and current liabilities rose materially versus year-end 2024. Management reiterated continued investments in AI and product development while noting market uncertainty and potential impacts on future earnings.